logo BDSP

Base documentaire

  1. Pharmacokinetic dosing in prophylactic treatment of hemophilia A.

    Article - En anglais

    The aim of this study was to investigate individual pharmacokinetics as a tool for dosing of factor VIII (FVIII) in severe hemophilia A. It is assumed that effective prophylaxis against bleedings is maintained if the plasma FVIII:C activity is kept above 1 U/dl, and the present study is based on this assumption.

    A current standard dosage regimen for FVIII is 25-40 U/kg up to three times weekly.

    However, there is considerable individual variation in the pharmacokinetics of FVIII:C. Individual pharmacokinetic data were used to computer-simulate plasma activity curves after repeated doses in 8 patients.

    Mots-clés Pascal : Hémophilie A, Pharmacocinétique, Dosage, Facteur antihémophilique A, Constituant sang, Prévention, Transfusion, Analyse coût efficacité, Economie santé, Suède, Europe, Homme, Hémopathie, Coagulopathie, Maladie héréditaire, Facteur coagulation, Traitement

    Mots-clés Pascal anglais : Hemophilia A, Pharmacokinetics, Assay, Factor VIII, Blood product, Prevention, Transfusion, Cost efficiency analysis, Health economy, Sweden, Europe, Human, Hemopathy, Coagulopathy, Genetic disease, Coagulation factor, Treatment

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0083053

    Code Inist : 002B27D01. Création : 199406.